Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 19/20 | 0.64 |
| ▸ | CA1 | P00915 | 12/20 | 0.64 |
| ▸ | CA12 | O43570 | 11/20 | 0.64 |
| ▸ | CA9 | Q16790 | 11/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.64 |
| ▸ | CA4 | P22748 | 5/20 | 0.64 |
| ▸ | CA6 | P23280 | 5/20 | 0.64 |
| ▸ | CA5A | P35218 | 5/20 | 0.64 |
| ▸ | CA7 | P43166 | 5/20 | 0.64 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309694 | 0.80 | CA2 (0.73) | CA2CA1CA12CA9CA14 | |
| SCHEMBL202948 | 0.79 | CA2 (0.81) | CA2CA1CA12CA9CA14 | |
| Sulfamide SCHEMBL5585371 | 0.78 | CA2 (0.70) | CA2CA1CA12CA9CA14 | |
| Mafenide SCHEMBL9295695 | 0.78 | CA2 (1.00) | CA2CA1CA12CA9CA14 | |
| SCHEMBL1804376 | 0.78 | CA2 (0.67) | CA2CA1CA12CA9CA14 | |
| Mafenide SCHEMBL41628 | 0.78 | CA2 (1.00) | CA2CA1CA12CA9CA14 | |
| SCHEMBL428943 | 0.77 | CA2 (0.62) | CA2CA1CA12CA9CA14 | |
| SCHEMBL17105794 | 0.77 | CA2 (0.61) | CA2CA1CA12CA9CA14 | |
| SCHEMBL13083212 | 0.76 | CA2 (0.64) | CA2CA1CA12CA9CA14 | |
| Mafenide SCHEMBL425524 | 0.76 | CA2 (1.00) | CA2CA1CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426429-B2 | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) | JANSSSEN PHARMACEUTICA N.V. (BE) | 2013-04-23 | — | — | US | claimed |
| EP-1776350-B1 | NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF ß-SECRETASE ( BACE ) | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-23 | — | — | EP | claimed |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | claimed |
| US-7960380-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | claimed |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | claimed |
| EP-1635839-B1 | BENZO[4,5]THIENO[2,3-D]PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2010-09-01 | — | — | EP | claimed |
| US-7723333-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | claimed |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | claimed |
| US-7470701-B2 | Substituted 2,5-heterocyclic derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | claimed |
| US-7465739-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-12-16 | — | — | US | claimed |
| US-20050038053-A1 | Novel compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-02-17 | — | — | US | claimed |
| WO-2004083207-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ABBOTT LABORATORIES (US) | 2004-09-30 | — | — | WO | claimed |
| US-20040029811-A1 | N-alkylglycine trimeres capable of protecting neurons against excitotoxic aggressions and compositions containing such trimeres | DIVERDRUGS, S.L. (ES) | 2004-02-12 | — | — | US | claimed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | claimed |
| EP-1338604-A1 | N-ALKYLGLYCINE TRIMERES CAPABLE OF PROTECTING NEURONS AGAINST EXCITOTOXIC AGGRESSIONS AND COMPOSITIONS CONTAINING SAID TRIMERES | Diverdrugs, S.L. (ES) | 2003-08-27 | — | — | EP | claimed |
| US-20020103381-A1 | Method for the synthesis of pyrazolines | CHEMRX ADVANCED TECHNOLOGIES, INC. | 2002-08-01 | — | — | US | claimed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001040193-A1 | METHOD FOR THE SYNTHESIS OF PYRAZOLINES | CHEMRX ADVANCED TECHNOLOGIES, INC. (US) | 2001-06-07 | — | — | WO | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029811-A1 | N-alkylglycine trimeres capable of protecting neurons against excitotoxic aggressions and compositions containing such trimeres | GRM1, GRM2, GRIN1 | CA2 3181/4885CA1 2307/4885CA12 4805/4885 |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | CA2 3449/4885CA1 3692/4885CA12 4594/4885 |
| US-20020103381-A1 | Method for the synthesis of pyrazolines | CYP2F1, CYP2E1, CYP3A7 | CA2 3403/4885CA1 1912/4885CA12 2538/4885 |
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | CA2 3109/4885CA1 2600/4885CA12 3880/4885 |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | CA2 1005/4885CA1 1832/4885CA12 3142/4885 |
| US-20050038053-A1 | Novel compounds and their use in therapy | HSD17B11, HSD17B2, HSD17B1 | CA2 3999/4885CA1 3205/4885CA12 2506/4885 |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | CA2 3449/4885CA1 3692/4885CA12 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.